作者: Aman U. Buzdar , Gabriel N. Hortobagyi , Francisco J. Esteva , Vicente Valero , Lajos Pusztai
DOI: 10.1634/THEONCOLOGIST.6-2-133
关键词: Combination chemotherapy 、 CA15-3 、 Internal medicine 、 Docetaxel 、 Medicine 、 Oncology 、 Vinorelbine 、 Breast cancer 、 Metastatic breast cancer 、 Epirubicin 、 Cancer
摘要: Chemotherapy plays an important role in the management of metastatic breast cancer. The anthracyclines (doxorubicin, epirubicin) and taxanes (paclitaxel, docetaxel) are considered most active agents for patients with advanced Traditionally, have been used combination cyclophosphamide 5-fluorouracil (FAC, FEC). single-agent activity similar to older chemotherapy treatments. There is great interest developing anthracycline/taxane combinations. Capecitabine indicated who progress after anthracycline taxane therapy. Vinorelbine gemcitabine cancer commonly as third- fourth-line palliative high-dose not well-defined remains experimental. Novel cytotoxic therapy strategies include development anthracycline, taxane, oral fluoropyrimidine analogues; antifolates; topoisomerase I inhibitors, multidrug resistance inhibitors. A better understanding biology providing novel treatment approaches. Oncogenes tumor-supressor genes emerging targets Trastuzumab, a monoclonal antibody directed against Her-2/neu protein, has shown prolong survival Other biologic therapies interfere signal transduction pathways angiogenesis. challenge next decade will be integrate these promising primary